| Business Summary | | Biomira
Inc.
is
a
product
focused
biotechnology
company
applying
its
proprietary
immunotherapy
and
organic
chemistry
technologies
for
the
development
of
cancer
therapeutics.
The
Company's
lead
product,
THERATOPE
vaccine,
is
currently
being
tested
in
a
Phase
III
clinical
trial
for
metastatic
breast
cancer.
The
Company's
commitment
to
the
development
of
products
for
the
treatment
of
cancer
is
focused
on
synthetic
therapeutic
vaccines
and
strategies
for
immunotherapeutic
treatment
of
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biomira,
Inc.
is
a
Canadian
biotechnology
company
utilizing
proprietary
and
patentable
methods
in
the
development,
manufacture
and
sale
of
therapeutic
products
for
the
treatment
of
cancer.
For
the
six
months
ended
6/30/01,
revenues
rose
92%
to
C$4.7
million.
Net
loss
rose
2%
to
C$22.9
million.
Results
reflect
increased
licensing,
royalties
and
research
contract
revenues,
offset
by
increased
expenditures
for
clinical
programs. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Eric Baker | Chairman | Alex McPherson, M.D., Ph.D. | Pres,
CEO | Mark Young, Ph.D. | COO | B. Michael Longnecker | Sr.
VP, R&D | Edward Taylor | VP,
Fin. and Admin., CFO and Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|